Department of Justice filed lawsuit against ValueAct Capital last week, related to Halliburton and Baker Hughes merger. Meanwhile, ValueAct on Monday claimed no wrongdoing and will defend its position.
Some top shareholders of IBM, disappointed by 11 straight quarters of falling revenues, are seeking help from activist investors to shake up the company, but have been turned down by both Bill Ackman's Pershing Square and Jeffrey Ubben's ValueAct, according to people with knowledge of the matter.
Activist hedge fund ValueAct Capital disclosed a 5.1 percent stake in Baker Hughes Inc (BHI.N), the world's No. 3 oilfield services company that has agreed to be bought by bigger rival Halliburton Co (HAL.N) for $35 billion in cash and stock.
Hedge fund ValueAct Capital said on Thursday it would return to the board of directors of Valeant Pharmaceuticals International Inc, which is pursuing a hostile takeover offer for Allergan Inc, and that it planned to increase its stake in the company.
Subscribe to VCpost newsletter
- Lance Armstrong's Next Ventures Raises $24.5 Million Of Expected $75 Million Fundraise
- Implied SPDR S&P MIDCAP 400 ETF Analyst Target Price: $389
- What This Centi-Billionaire Fashion Magnate Can Teach You About Investing
- ADP vs. Paychex: Comparing Key Metrics For The Two Largest Payroll Processing Companies
- After Energy Sector Earnings Plunge In Q1, Hopes Rise For Improved Q2 Performance
- Are Strong Jobs Really Bad For Stocks?
- 4 Price Charts You Should See: Bank Stocks Are Showing Relative Weakness
- Citigroup's $21.5-Billion Capital Return Plan For 2019 Is Slightly Lower Than Its 2018 Plan